S-892216
- Generic Name
- S-892216
Shionogi Advances Development of Long-Acting COVID-19 Antiviral with BARDA Support
Shionogi & Co., Ltd. has been awarded a $375 million project agreement by BARDA to develop S-892216, a long-acting injectable antiviral for COVID-19 pre-exposure prophylaxis. This initiative aims to address the unmet need for effective pre-exposure prophylaxis therapeutics, with phase 1 studies expected to begin in 2025. S-892216, a second-generation 3CL protease inhibitor, has shown strong antiviral effects in pre-clinical trials and is being developed in both injectable and oral forms.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath